한빛사논문
Jong-Chan Parka,1,2, Sun-Ho Hana,b,1,2, Hangyeore Leec,1,2, Hyobin Jeongd,e,1,2, Min Soo Byunf,1,2, Jingi Baec,2, Hokeun Kimc,2, Dong Young Leef,g,h,2, Dahyun Yif,2, Seong A Shini,2, Yu Kyeong Kimi,2, Daehee Hwangd,j,2,*, Sang-Won Leec,2,*, Inhee Mook-Junga,b,2,*
a Department of Biochemistry and Biomedical Sciences, College of Medicine, Seoul National University, Seoul, 03080, Republic of Korea
b Neuroscience Research Institute, College of Medicine, Seoul National University, Seoul, 03080, Republic of Korea
c Department of Chemistry, Center for Proteogenome Research, Korea University, Seoul, 02841, Republic of Korea
d Center for Plant Aging Research, Institute for Basic Science, Daegu Gyeongbuk Institute of Science and Technology, Daegu, 42988, Republic of Korea
e European Molecular Biology Laboratory (EMBL), Genome Biology Unit, Meyerhofstr. 1, 69117, Heidelberg, Germany
f Institute of Human Behavioral Medicine, Medical Research Center, Seoul National University, Seoul, Republic of Korea
g Department of Psychiatry, College of medicine, Seoul National University, Seoul, Republic of Korea
h Department of Neuropsychiatry, Seoul National University Hospital, Seoul, Republic of Korea
i Department of Nuclear Medicine, SMG-SNU Boramae Medical Center, Seoul, Republic of Korea
j Department of Biological Sciences, Seoul National University, Seoul, 08826, Republic of Korea
*Corresponding author : Daehee Hwang, Sang-Won Lee, Inhee Mook-Jung
1Equally contributed first authors.
2Information on the KBASE Research Group is provided in elsewhere (http://kbase.kr/eng/about/research.php).
Abstract
Alzheimer’s disease (AD) is the most common age-associated dementia. Many studies have sought to predict cerebral amyloid deposition, the major pathological hallmark of AD, using body fluids such as blood or cerebral spinal fluid (CSF). The use of blood in diagnostic procedures is widespread in medicine; however, existing blood biomarkers for AD remain unreliable. We sought to discover blood biomarkers that discriminate Aβ deposition status in the brain. This study used 107 individuals who were cognitively normal (CN), 107 patients with mild cognitive impairment (MCI), and 40 AD patients with Pittsburg compound B positron emission tomography (PiB-PET) amyloid imaging data available. We found five plasma biomarker candidates via mass spectrometry (MS) based-proteomic analysis and validated these proteins using enzyme-linked immunosorbent assay (ELISA). Our integrated models were highly predictive of brain amyloid deposition, exhibiting 0.871 accuracy with 79% sensitivity and 84% specificity overall, and 0.836 accuracy with 68% sensitivity and 90% specificity in patients with MCI. These results indicated that a combination of proteomic-based blood proteins might be a possible biomarker set for predicting cerebral amyloid deposition.
Abbreviation
ACE, angiotensin-converting enzyme; AD, Alzheimer’s disease; ANCOVA, analysis of covariance; ANOVA, analysis of variance; ATRN, attractin; AUC, area under the curve; AZGP1, zinc-alpha-2-glycoprotein precursor; CDH5, vascular endothelial cadherin 5; CN, cognitively normal; CPN2, carboxypeptidase N subunit 2; CSF, cerebrospinal fluid; CV, covariates; DE, differentially expressed; ELISA, enzyme-linked immunosorbent assay; ERAP2, endoplasmic reticulum aminopeptidase 2; IRB, Institutional Review Board; KBASE, Korean Brain Aging Study for the Early Diagnosis and Prediction of Alzheimer’s Disease; LGALS3BP, galectin-3-binding protein; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; MRI, magnetic resonance imaging; MS, mass spectrometry; NRI, net reclassification improvement; PiB-PET, Pittsburg compound B positron emission tomography; POSTN, periostin; ROC, receiver operating characteristic; RR, relative risk; TMT, tandem mass tag; VWF, von Willebrand factor; α2M, alpha-2-macroglobulin
Keywords : Alzheimer’s disease; Proteomics; PiB-PET; Plasma biomarker; TMT; Cerebral amyloid deposition
논문정보
관련 링크
연구자 키워드
연구자 ID
관련분야 연구자보기
관련분야 논문보기